These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37061271)

  • 1. Brimonidine.
    Bakheit AH; Alomar AM; Darwish H; Alkahtani HM
    Profiles Drug Subst Excip Relat Methodol; 2023; 48():1-37. PubMed ID: 37061271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension.
    Adkins JC; Balfour JA
    Drugs Aging; 1998 Mar; 12(3):225-41. PubMed ID: 9534022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brimonidine tartrate for the treatment of glaucoma.
    Oh DJ; Chen JL; Vajaranant TS; Dikopf MS
    Expert Opin Pharmacother; 2019 Jan; 20(1):115-122. PubMed ID: 30407890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment.
    Greenfield DS; Liebmann JM; Ritch R
    J Glaucoma; 1997 Aug; 6(4):250-8. PubMed ID: 9264305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of brimonidine in children with glaucoma.
    Enyedi LB; Freedman SF
    J AAPOS; 2001 Oct; 5(5):281-4. PubMed ID: 11641636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of brimonidine on aqueous humor dynamics in human eyes.
    Toris CB; Gleason ML; Camras CB; Yablonski ME
    Arch Ophthalmol; 1995 Dec; 113(12):1514-7. PubMed ID: 7487618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2.
    Schuman JS
    Ophthalmology; 2000 Jun; 107(6):1171-7. PubMed ID: 10857839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial.
    DuBiner HB; Mroz M; Shapiro AM; Dirks MS;
    Clin Ther; 2001 Dec; 23(12):1969-83. PubMed ID: 11813932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical evaluation of brimonidine.
    Burke J; Schwartz M
    Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S9-18. PubMed ID: 8970245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evolving pharmacotherapeutic profile of brimonidine, an alpha 2-adrenergic agonist, after four years of continuous use.
    Cantor LB
    Expert Opin Pharmacother; 2000 May; 1(4):815-34. PubMed ID: 11249518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative acute effects of brimonidine 0.2% versus dorzolamide 2% combined with beta-blockers in glaucoma.
    Centofanti M; Manni G; Gregori D; Cocco F; Lorenzano D; Bucci MG
    Graefes Arch Clin Exp Ophthalmol; 2000 Apr; 238(4):302-5. PubMed ID: 10853928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension.
    Stewart WC; Day DG; Stewart JA; Holmes KT; Leech JN; Rowan CT; Schwartz GF
    J Ocul Pharmacol Ther; 2000 Dec; 16(6):557-64. PubMed ID: 11132902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical brimonidine 0.2%/timolol 0.5% ophthalmic solution: in glaucoma and ocular hypertension.
    Frampton JE
    Drugs Aging; 2006; 23(9):753-61. PubMed ID: 17020399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension.
    Aung T; Laganovska G; Hernandez Paredes TJ; Branch JD; Tsorbatzoglou A; Goldberg I
    Ophthalmology; 2014 Dec; 121(12):2348-55. PubMed ID: 25064721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
    Stewart WC; Sharpe ED; Day DG; Kolker AE; Konstas AG; Lee WH; Rieser JC; Chopra H; Holmes KT
    J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of brimonidine 0.2% on blue-yellow perimetry of glaucomatous patients.
    Mastropasqua L; Ciancaglini M; Carpineto P; Zuppardi E; Falconio G; Gallenga PE
    Acta Ophthalmol Scand Suppl; 1998; (227):36. PubMed ID: 9972338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
    LeBlanc RP
    Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The short-term effect of adding brimonidine 0.2% to timolol treatment in patients with open-angle glaucoma.
    Yüksel N; Altintaş O; Karabaş L; Alp B; Cağlar Y
    Ophthalmologica; 1999; 213(4):228-33. PubMed ID: 10420106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the short-term hypotensive effects and side effects of unilateral brimonidine and apraclonidine in patients with elevated intraocular pressure.
    Yüksel N; Karabaş L; Altintaş O; Yildirim Y; Cağlar Y
    Ophthalmologica; 2002; 216(1):45-9. PubMed ID: 11901288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute and chronic effects of brimonidine 0.2% on intraocular pressure and pulsatile ocular blood flow in patients with primary open-angle glaucoma: an open-label, uncontrolled, prospective study.
    Vetrugno M; Maino A; Cantatore F; Ruggeri G; Cardia L
    Clin Ther; 2001 Sep; 23(9):1519-28. PubMed ID: 11589264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.